DalsnaFinance Account

Edwards Lifesciences $EW

Health Care · Health Care Equipment · NYSE/NASDAQ

S&P 500 Russell 1000 California

Create a scorecard

$88.01

+0.79 (+0.91%)

As of Oct 20, 2026, 12:08 PM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 21, 2026, the first target we tracked for EW.

Key facts

52-week range (closes): $72.65 – $95.18 Lowest close Oct 16, 2025, highest Jul 6, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends: December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since: Mar 31, 2011 · All S&P 500 changes
Analyst coverage: 1 open price target from 1 firm: TD Cowen Approved targets tracked here; see the analyst section below

Edwards Lifesciences (EW) is trading up at $88.01 (+0.91%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on EW

One firm's current price target on Edwards Lifesciences: $104 — 18% above the current $88. Each is tracked to its date and scored the same way a member's call is.

TD Cowen $84.5 → $104 by Jul 2027 Buy Jul 21, 2026 via Investing.com · TD Cowen's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Edwards Lifesciences revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Edwards Lifesciences annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$2.96B	$3.44B	$3.72B	$4.35B	$4.39B	$5.23B	$4.46B	$5.01B	$5.44B	$6.07B
Growth (year over year)	+18.8%	+15.9%	+8.4%	+16.8%	+0.9%	+19.3%	−14.7%	+12.2%	+8.6%	+11.5%
Gross profit	$2.17B	$2.56B	$2.78B	$3.23B	$3.31B	$3.98B	$3.74B	$4.03B	$4.32B	$4.73B
Gross margin	73.1%	74.5%	74.8%	74.4%	75.4%	76.1%	83.8%	80.5%	79.5%	78.0%
Operating income	$751.2M	$1.09B	$748.2M	$1.15B	$897.6M	$1.69B	$1.50B	$1.31B	$1.38B	$1.26B
Operating margin	25.3%	31.7%	20.1%	26.4%	20.5%	32.3%	33.6%	26.1%	25.3%	20.8%
Net income	$569.5M	$583.6M	$722.2M	$1.05B	$823.4M	$1.50B	$1.52B	$1.40B	$4.17B	$1.07B
Net margin	19.2%	17.0%	19.4%	24.1%	18.8%	28.7%	34.1%	28.0%	76.7%	17.7%
EPS (diluted)	$0.87	$0.90	$1.13	$1.64	$1.30	$2.38	$2.44	$2.30	$6.97	$1.83
Balance sheet
Cash and equivalents	$930.1M	$818.3M	$714.1M	$1.18B	$1.18B	$862.8M	$769.0M	$1.13B	$3.05B	$2.94B
Total assets	$4.51B	$5.67B	$5.32B	$6.49B	$7.24B	$8.50B	$8.29B	$9.36B	$13.1B	$13.7B
Total liabilities	$1.89B	$2.71B	$2.18B	$2.34B	$2.66B	$2.67B	$2.49B	$2.64B	$2.99B	$3.36B
Long-term debt	$822.3M	$438.4M	$593.8M	$594.4M	$595.0M	$595.7M	$596.3M	$597.0M	$597.7M	$598.3M
Shareholders' equity	$2.62B	$2.96B	$3.14B	$4.15B	$4.57B	$5.84B	$5.81B	$6.65B	$10.00B	$10.3B
Cash flow
Operating cash flow	$704.4M	$1.00B	$926.7M	$1.18B	$1.05B	$1.73B	$1.22B	$895.8M	$542.3M	$1.60B
Capital expenditure	$176.1M	$168.1M	$238.7M	$254.4M	$407.0M	$325.8M	$244.6M	$253.0M	$252.4M	$260.2M
Free cash flow	$528.3M	$832.6M	$688.0M	$928.5M	$647.3M	$1.41B	$973.6M	$642.8M	$289.9M	$1.33B
Share buybacks	$662.3M	$763.3M	$795.5M	$263.3M	$625.4M	$512.8M	$1.73B	$879.6M	$1.16B	$893.4M

RevenueNet incomeNet margin (right axis, %)

Edwards Lifesciences quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$1.35B	$1.39B	$1.41B	$1.53B	$1.55B	$1.57B	$1.65B	$1.74B
Growth (year over year)	+8.9%	+9.4%	+6.2%	+11.9%	+14.7%	+13.3%	+16.7%	+13.6%
Gross profit	$1.09B	$1.09B	$1.11B	$1.19B	$1.21B	$1.23B	$1.29B	$1.35B
Gross margin	80.6%	78.9%	78.7%	77.5%	77.8%	78.1%	78.0%	77.5%
Operating income	$350.6M	$312.6M	$394.8M	$411.2M	$307.1M	$151.1M	$477.6M	$513.2M
Operating margin	25.9%	22.6%	27.9%	26.8%	19.8%	9.6%	29.0%	29.5%
Net income	$3.07B	$385.6M	$358.0M	$333.2M	$291.1M	$91.2M	$380.7M	$241.9M
Net margin	226.7%	27.8%	25.3%	21.7%	18.7%	5.8%	23.1%	13.9%
EPS (diluted)	$5.13	$0.65	$0.61	$0.56	$0.50	$0.16	$0.66	$0.42
Balance sheet
Cash and equivalents	$3.68B	$3.05B	$3.14B	$3.27B	$2.69B	$2.94B	$2.45B	$2.91B
Total assets	$13.0B	$13.1B	$13.0B	$13.5B	$13.3B	$13.7B	$13.3B	$13.9B
Total liabilities	$3.36B	$2.99B	$2.83B	$2.88B	$3.07B	$3.36B	$2.99B	$3.14B
Long-term debt	$597.5M	$597.7M	$597.8M	$598.0M	$598.2M	$598.3M	$598.5M	$598.7M
Shareholders' equity	$9.55B	$10.00B	$10.1B	$10.5B	$10.2B	$10.3B	$10.3B	$10.6B
Cash flow
Operating cash flow	$351.8M	−$127.5M	$280.4M	$290.2M	$573.7M	$450.9M	$43.8M	$651.9M
Capital expenditure	$51.9M	$49.8M	$56.0M	$49.3M	$57.5M	$97.4M	$64.9M	$66.9M
Free cash flow	$299.9M	−$177.3M	$224.4M	$240.9M	$516.2M	$353.5M	−$21.1M	$585.0M
Share buybacks	$901.0M	$100.1M	$258.6M	$5.50M	$588.7M	$40.6M	$421.8M	$153.3M

From Edwards Lifesciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Edwards Lifesciences vs the Health Care sector and the S&P 500

Edwards Lifesciences's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Edwards Lifesciences compared with the median Health Care company and the median S&P 500 company
Measure	Edwards Lifesciences	Health Care (59 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	+11.5%	+7.1%	+7.0%
Net margin, latest fiscal year	17.7%	12.9%	12.9%
Share price change, 1 year	+15.8%	+19.8%	+5.6%

Edwards Lifesciences: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Edwards Lifesciences included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.

About Edwards Lifesciences

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.

Source: Wikipedia — Edwards Lifesciences